122 completed, 6 terminated, 5 not yet recruiting, 5 recruiting. 145 Phase 2, 11 Phase 1, 9 Phase 3.
Follow Hypercholesterolemia: new trials by email Literature Review of Hypercholesterolemia trials Research Report on Hypercholesterolemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RCT for the Chinese Medicine in Treating Hypercholesterolemia Dachaihu Decoction combined Erzhiwan with variation, Placebo granules - Hypercholesterolemia | Phase 2 | Not yet recruiting | Chinese University of Hong Kong | 70 | 2027-01-01 | 2026-07-30 |
| EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C) Drug: EDIT-401, Placebo - Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 1 / Phase 2 | Not yet recruiting | Editas Medicine, Inc. | 56 | 2026-11-01 | 2026-10-26 |
| A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease VERVE-102, Placebo - Atherosclerosis, Cardiovascular Disease | Phase 2 | Recruiting | Verve Therapeutics, Inc. | 175 | 2026-09-24 | 2026-11-10 |
| Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study Colesevelam, Placebo - PFAS, Environmental Exposures | Phase 2 | Not yet recruiting | University of Rhode Island | 50 | 2026-07-01 | 2026-05-18 |
| A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia Alirocumab - Hypercholesterolemia | Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 438 | 2026-06-17 | 2026-10-15 |
| A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia QCZ484, Inclisiran, QCZ484 placebo - Hypercholesterolaemia | Phase 2 | Recruiting | Novartis Pharmaceuticals | 120 | 2026-05-29 | 2026-07-30 |
| Vascular Intervention Strategies Trial for Alzheimer's Angiotensin Receptor Blockers (ARBs), Hydrophilic Statins or Non-Statin Alternative - Hypertension, Hypercholesterolemia | Phase 2 | Not yet recruiting | University of Southern California | 10 | 2026-05-01 | 2026-05-04 |
| A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors SHR-1918 Injection, SHR-1918 Injection Placebo - Hypercholesterolemia | Phase 2 / Phase 3 | Recruiting | Beijing Suncadia Pharmaceuticals Co., Ltd | 126 | 2026-04-30 | 2026-06-16 |
| DNV001 Injection in Patients With Hypercholesterolemia DNV001 Injection, Placebo - Primary Hypercholesterolemia | Phase 2 | Not yet recruiting | Hangzhou Dinovate Biotech Co., Ltd | 120 | 2026-02-05 | 2026-02-06 |
| Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis statin + ezetimibe, Statin monotherapy (rosuvastatin or atorvastatin) - Ischemic Stroke, Hypercholesteremia | Phase 2 | Recruiting | Chang Gung Memorial Hospital | 300 | 2025-08-01 | 2025-12-30 |
| A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia SYH2053/placebo injection, Inclisiran (Leqvio®) 300mg - Hypercholesterolemia and Mixed Hyperlipidemia | Phase 2 | Completed | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 156 | 2024-12-03 | 2026-02-19 |
| Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists RDX-002, Placebo - Triglycerides, Weight Gain Trajectory | Phase 2 | Completed | Response Pharmaceuticals | 68 | 2024-09-27 | 2026-07-02 |
| Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial Statin (rosuvastatin 10 or 40 mg daily, depending on risk), Healthy Lifestyle Counseling, Outpatient Followup - Lipid Disorder, Hypercholesterolemia | Phase 2 | Recruiting | Wake Forest University Health Sciences | 130 | 2024-08-05 | 2026-02-27 |
| Effects of Phytoestrogen From Pueraria Mirifica in Improvement of Serum Lipid Parameters in Postmenopausal Women Phytoestrogen, Diet control & life style modification - Dyslipidemias, Hypertriglyceridemia | Phase 2 / Phase 3 | Unknown | Dhurakij Pundit University | 10 | 2024-03-02 | 2024-05-24 |
| A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia SAL003 140mg+Atorvastatin, SAL003 420mg+Atorvastatin, Placebo 140mg+Atorvastatin - Hypercholesterolemia and Mixed Dyslipidemia | Phase 2 | Completed | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 214 | 2023-06-02 | 2025-12-12 |
| Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease（NAFLD） HSK31679 low dose, HSK31679 medium dose, HSK31679 high dose - Hypercholesterolemia | Phase 2 | Completed | Haisco Pharmaceutical Group Co., Ltd. | 210 | 2023-04-26 | 2024-04-09 |
| A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1) Bempedoic acid - Hypercholesterolemia | Phase 2 | Completed | Esperion Therapeutics, Inc. | 31 | 2023-01-12 | 2026-07-17 |
| A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. Obicetrapib, Placebo - Dyslipidemia, Hypercholesterolemia | Phase 2 | Completed | NewAmsterdam Pharma | 102 | 2022-06-27 | 2024-10-29 |
| A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008) Enclitide Chloride, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia | Phase 2 | Completed | Merck Sharp & Dohme LLC | 381 | 2022-03-10 | 2024-12-09 |
| Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy Obicetrapib, Ezetimibe 10mg, Obicetrapib placebo - Dyslipidemias, High Cholesterol | Phase 2 | Completed | NewAmsterdam Pharma | 119 | 2022-03-09 | 2024-07-03 |
Showing 20 of 145. Sign in to see all of them.
Dyslipidemias (25) · Hyperlipidemias (21) · Cardiovascular Diseases (12) · Atherosclerosis (9) · Hypertension (9) · Hypertriglyceridemia (9) · Hyperlipoproteinemia Type II (8) · Lipid Metabolism Disorders (8) · Metabolic Diseases (7) · Metabolic Syndrome (5) · Obesity (5) · Diabetes Mellitus (4) · Coronary Artery Disease (3) · Coronary Disease (3)
Nutritional and Metabolic Diseases (143) · Metabolic Diseases (138) · Lipid Metabolism Disorders (137) · Hyperlipidemias (124) · Dyslipidemias (120) · Vascular Diseases (23) · Cardiovascular Diseases (18) · Arterial Occlusive Diseases (11) · Arteriosclerosis (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Glucose Metabolism Disorders (10) · Pathological Conditions, Signs and Symptoms (10) · Genetic Diseases, Inborn (9) · Endocrine System Diseases (8) · Hyperlipoproteinemias (7)
Atorvastatin (22) · Ezetimibe (14) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (9) · alirocumab (9) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (8) · evolocumab (8) · Rosuvastatin Calcium (6) · gemcabene (5) · mipomersen (5) · Pravastatin (4) · bococizumab (4) · 1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid (3) · 3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid (3) · BMS201038 (3) · ALN-PCS (2)
Esperion Therapeutics, Inc. (9) · Amgen (7) · Kastle Therapeutics, LLC (5) · NeuroBo Pharmaceuticals Inc. (5) · Regeneron Pharmaceuticals (5) · Sanofi (5) · Merck Sharp & Dohme LLC (4) · Micropharma Limited (4) · National Center for Complementary and Integrative Health (NCCIH) (4) · National Heart, Lung, and Blood Institute (NHLBI) (4) · NewAmsterdam Pharma (4) · Pfizer (4) · Aegerion Pharmaceuticals, Inc. (3) · Eli Lilly and Company (3) · Karo Bio AB (3)
United States (72) · Canada (29) · Netherlands (12) · Japan (11) · Australia (10) · China (8) · Czechia (8) · Denmark (8) · Spain (8) · France (7) · Sweden (7) · Germany (6) · Italy (6) · United Kingdom (6) · Belgium (5)
Ron Haberman, MD (2) · Adrian Di Bisceglie, MD,FACP,FAASLD (1) · Alison L Gibbs, PhD (1) · Angela Slitt, PhD (1) · Annabelle Rodriguez, MD (1) · Arshed A Quyyumi, MD (1) · Barry Lubin, MD (1)
PMID 30183102, PMID 37994400, PMID 26872608, PMID 20707601, PMID 21518985, PMID 24014831, PMID 25060413, PMID 28181260, PMID 29037448, PMID 16996859, PMID 17030154, PMID 17298834, PMID 17325296, PMID 17384435, PMID 17392721, PMID 17434849, PMID 17556685, PMID 17987126, PMID 19364997, PMID 19500003, PMID 19506174, PMID 19810001, PMID 19843338, PMID 20008831, PMID 20220185, PMID 20378080, PMID 20428452, PMID 20527967, PMID 20660224, PMID 20668250, PMID 20875216, PMID 21593041, PMID 21982664, PMID 22089718, PMID 22118569, PMID 22264573, PMID 22301925, PMID 22463922, PMID 22484031, PMID 22507979, PMID 22561556, PMID 22633824, PMID 22698766, PMID 23113833, PMID 23148122, PMID 23174266, PMID 23221573, PMID 23262496, PMID 23840361, PMID 23884353
2005 (1), 2015 (1), 2017 (1), K23HL169929 (1), R01HL042554 (1), R01HL070742 (1), U01HL044315 (1)